The 5-HT 2A -serotonin receptor is a major molecular target for most atypical antipsychotic drugs as well as most hallucinogens, which can exacerbate psychotic symptoms. In this study, we examined whether random sequence variations in the gene (single nucleotide polymorphisms, SNPs) encoding the 5-HT 2A -serotonin receptor could explain inter-individual variability in atypical antipsychotic and agonist drug response. We examined the in vitro pharmacology of four non-synonymous SNPs, which give rise to T25N, I197V, A447V, and H452Y variant 5-HT 2A -serotonin receptors. Our data indicate that these non-synonymous SNPs exert statistically significant, although modest, effects on the affinity and functional effects of several currently approved atypical antipsychotics (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone). Also, the 5-HT 2A receptor SNPs slightly altered the potency and relative efficacy of a small number of selected agonists (2,5-dimethoxy-4-iodoamphetamine, tryptamine, 5-hydroxytryptamine, m-chlorophenylpiperazine, and 5-methoxy-N, N-dimethyltryptamine). In all, our results show that the in vitro pharmacological effects of the SNPs are drug specific.
Introduction
Drug therapy for schizophrenia consists primarily of typical and atypical antipsychotic drugs that have as their proximal molecular targets dopamine (DA) and serotonin (5-hydroxytryptamine; 5-HT) G-protein-coupled receptors (GPCRs). [1] [2] [3] While typical antipsychotic drugs (e.g., chlorpromazine, haloperidol, and fluphenazine) demonstrate potent DA D 2 receptor blockade and effectively treat the positive symptoms of schizophrenia, atypical antipsychotic drugs (e.g., clozapine, olanzapine, quetiapine, risperidone, and ziprasidone) demonstrate a higher affinity for serotonin (particularly 5-HT 2A ) receptors than for D 2 receptors, [3] [4] [5] and effectively treat both the positive and negative symptoms of schizophrenia. Aripiprazole is an unusual atypical antipsychotic drug that has functionally selective partial agonist actions at D 2 receptors and several 5-HT receptor subtypes. 6 Clinical studies indicate that schizophrenics who take atypical antipsychotic drugs exhibit a wide variability in drug response. In fact, 30-60% of schizophrenics 7, 8 and between 10 and 65% of individuals with treatment-resistant major depression 9 do not improve following atypical antipsychotic therapy; others experience uncomfortable side effects that could influence compliance 10 and/or adverse events that may be life threatening. 11 The reasons for inter-individual variability in atypical antipsychotic drug response have not been convincingly elucidated.
At the molecular level, random sequence variations in genes (single nucleotide polymorphisms, SNPs) 12, 13 could explain inter-individual differences in atypical antipsychotic drug response, although despite much study there is still no consensus regarding GPCR SNPs and atypical antipsychotic drug responses. 11, 14 It is likely that the lack of a consensus regarding the relationship between GPCR SNPs and antipsychotic drug responses stems in large measure from our ignorance regarding the functional implications of various coding and non-coding SNPs for drug actions at various GPCRs. Indeed, without some insight into the potential functional consequences of a particular SNP for a particular medication, studies aimed at elucidating drug responses are not likely to be adequately designed or powered. Accordingly, we have begun a comprehensive survey of atypical antipsychotic drug actions at various polymorphic GPCRs implicated in antipsychotic drug actions as a prelude to clinical trials aimed at elucidating the effects of various SNPs on antipsychotic drug responses. In this, our initial survey, we have focused on the serotonin 5-HT 2A receptor because it is a major molecular target for many atypical antipsychotic drugs and some antidepressants, 3, 15 as well as classical hallucinogens like LSD and psilocybin [16] [17] [18] [19] that mimic and exacerbate psychotic symptoms.
The 5-HT 2A -serotonin receptor is a GPCR whose activation leads to the stimulation of the enzyme phospholipase C and to the subsequent hydrolysis of the membrane phosphoinositides, with the synthesis of the second messengers inositol triphosphate and diacylglycerol. 4, 20 At least seven SNPs are located within the coding region of the human 5-HT 2A receptor gene (HTR2A, 13q14-21) (Figure 1) . Two of the seven nucleotide polymorphisms (T102C and C516T) do not alter the 5-HT 2A receptor amino-acid sequence (i.e., are synonymous SNPs). The remaining five nucleotide polymorphisms (T25N, I197V, S421F, A447V, and H452Y) result in amino-acid mutations (i.e., are non-synonymous SNPs) and, thus, potentially affect receptor structure/function. As demonstrated in Figure 1 , based on molecular models of the 5-HT 2A receptor that have been validated by extensive molecular pharmacological studies, [21] [22] [23] [24] the T25N SNP maps to the predicted N-terminal tail of the receptor; the I197V SNP resides in the putative second intracellular loop (i2); the three remaining non-synonymous SNPs (A447V, S421F, and H452Y) are located within the putative C-terminal tail. Both i2 and the C-terminal tail have been implicated in G-protein coupling of the 5-HT 2A -serotonin receptor. 22, 24 Among the 5-HT 2A receptor functional SNPs, the rarer allele frequencies vary from 0.7 (A447V) to 9.3% (H452Y). 25 Although many clinical studies have examined the relationship between various synonymous and non-synonymous 5-HT 2A receptor SNPs and clinical responses to a variety of antipsychotic drugs, 11, [26] [27] [28] [29] [30] there is a lack of consensus regarding the clinical relevance of the findings. Additionally, although many polymorphisms have been extensively examined -especially the silent T102C polymorphism and the H452Y polymorphism -no published studies have examined the relationship between three of the functional variants (I197V, A447V, and S421F) and drug response. In the current study, we comprehensively examined antipsychotic affinity and functional activity for all currently US FDA-approved atypical antipsychotic drugs at several 5-HT 2A non-synonymous SNPs. We also examined agonist potency and relative efficacy for several 5-HT 2A agonists. We discovered that the effects of individual SNPs were drug selective and that no single SNP had effects on all antipsychotic drugs tested. These results imply that future clinical studies should be designed to examine particular drug-SNP combinations -paying particular attention to those combinations that have significant differences in the in vitro pharmacologies of test agents.
Results
Atypical antipsychotic affinities differ minimally between wild-type and polymorphic 5-HT 2A receptors To determine whether naturally occurring, non-synonymous SNPs in the 5-HT 2A receptor are likely to affect atypical antipsychotic actions in vivo, we measured the in vitro affinity of the wild-type, T25N, I197V, A447V, and H452Y 5-HT 2A receptors for all current US FDA-approved atypical antipsychotics including aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone. As shown in Figure 2 and Table 1 , three of the four polymorphic 5-HT 2A receptors exhibited statistically significant, although modest, changes in atypical antipsychotic affinity. Of these, the largest effect was observed for the I197V 5-HT 2A receptor, which displayed a twofold increase in affinity for aripiprazole compared to the wild type (60 vs 150 nM, Po0.05). None of the other SNP-induced alterations in atypical antipsychotic affinity was greater than twofold, although in some instances there was a significant difference (Po0.05) from the wild-type value. Atypical antipsychotic apparent antagonist potency at wild-type and polymorphic 5-HT 2A receptors AS a point mutation in the 5-HT 2A receptor could affect the functional activity of a drug without changing its affinity, 23, 24 we estimated the apparent antagonist potency of the atypical antipsychotics listed above -with the exception of aripiprazole, which we previously identified as a 5-HT 2A receptor partial agonist 6 -at wild-type and polymorphic 5-HT 2A receptors.
As shown in Figure 3 and Table 2 , we measured a 10-fold increase in clozapine's apparent antagonist potency at the I197V 5-HT 2A receptor compared to the wild type (4 vs 40 nM, Po0.05). Clozapine's apparent antagonist potency was not altered by any other SNP. We measured a fourfold increase in quetiapine's apparent antagonist potency at the T25N 5-HT 2A receptor compared to the wild type (100 vs 400 nM); we also measured a threefold increase in risperidone's apparent antagonist potency at the H452Y 5-HT 2A receptor compared to the wild type (2 vs 6 nM, Po0.05). Olanzapine and ziprasidone did not exhibit any threefold or greater differences in apparent antagonist potency at any of the variant 5-HT 2A receptors compared to the wild type.
Agonist potency (pEC 50 ) and relative efficacy (E max ) at wild-type and polymorphic 5-HT 2A receptors Having addressed whether several widely prescribed atypical antipsychotics exhibit differential in vitro pharmacologies at wild-type and polymorphic 5-HT 2A receptors, we next investigated agonist potency. As shown in Figure 4 and Table 3 , the potency of three tryptamines (5-HT, 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), and tryptamine) at the H452Y 5-HT 2A receptor -was altered greater than threefold compared to the wild type. Specifically, 5-HT potency was decreased fourfold compared to the wild type (68 vs 16 nM, Po0.05); 5-methoxy-DMT potency was also reduced fourfold compared to the wild type (8 vs 2 nM, Po0.05). In contrast to the derivatives 5-HT and 5-MeO-DMT, both of which displayed a fourfold decrease in potency at the H452Y 5-HT 2A receptor, the potency of the parent compound tryptamine at the H452Y 5-HT 2A receptor was increased fourfold compared to the wild type (60 vs 250 nM, Po0.05). In addition, tryptamine was less potent at the T25N 5-HT 2A receptor than at the wild-type receptor (680 vs 250 nM, Po0.05).
The 5-HT 2B/2C receptor-preferring piperazine m-chlorophenylpiperazine (mCPP) displayed a significant 10-fold increase in potency at the I197V 5-HT 2A receptor compared to the wild type (pEC 50 values of 7.9 and 6.8, respectively). At the H452Y 5-HT 2A receptor, the drug displayed a 10-fold increase in potency compared to the wild type (20 vs 200 nM, Po0.05) ( Figure 4 and Table 3 ). The potency of mCPP at the T25N and A447V polymorphic 5-HT 2A receptors was not significantly different from the wild-type value.
The hallucinogenic phenylisopropylamine 2,5-dimethoxy-4-iodoamphetamine (DOI) displayed a 10-fold decrease in potency for the H452Y 5-HT 2A receptor compared to the wild type (10 vs 1 nM, Po0.05) ( Figure 4 and Table 3 ). At the T25N 5-HT 2A receptor, we measured a fourfold decrease in potency compared to the wild type (4 vs 1 nM, Po0.05) ( Figure 4 and Table 3 ). DOI potency was not altered from the wild-type value by I197V and A447V 5-HT 2A polymorphisms.
The quinolinone atypical antipsychotic 7-{4-butyloxy}-3,4-dihydro-2(1H)-quinolinone (aripiprazole) has been classified by some investigators as a 5-HT 2A receptor antagonist, based on limited study. [31] [32] [33] We, however, have reported Table 1 for the complete data matrix.
-and confirm herein -that aripiprazole is a weak partial agonist at the 5-HT 2A receptor (EC 50 ¼ 1 nM; Figure 4 and Table 3 ). At the T25N 5-HT 2A receptor, aripiprazole exhibits a 30-fold decrease in potency compared to the wild type (30 vs 1 nM, Po0.05) ( Figure 4 and Table 3 ). The potency of aripiprazole did not differ more than twofold from the wildtype value at any of the other variant 5-HT 2A receptors ( Figure 4 and Table 3 ).
In order to determine whether any of the 5-HT 2A receptor polymorphisms affected agonist-mediated receptor activation, we measured the maximal responses (relative to the maximum response to 5-HT) of wild-type and variant 5-HT 2A receptors to several agonists. As shown in Figure 5 and Table 4 , the I197V 5-HT 2A receptor displayed significant alterations from the wild type in relative E max for all the agonists examined herein. For the tryptamines 5-OMe-DMT and tryptamine, the relative E max was decreased 29 and 22%, respectively, compared to the wild type (5-OMe-DMT: 44 vs 62, Po0.05; tryptamine: 56 vs 72, Po0.05). The relative efficacy of the piperazine mCPP was increased 67% at the I197V 5-HT 2A receptor compared to the wild type (30 vs 18, Po0.05). The relative E max of the phenylisopropylamine slope þ 10 log A2 )Àlog C, where the slope is the Schild slope, [B] is the concentration of atypical antipsychotic, and A2 is the concentration of antagonist that causes a twofold increase in EC 25 . 49 See Table 2 for the complete data matrix. DOI was decreased 36% by the I197V SNP compared to the wild-type value (36 vs 56, Po0.05). Finally, the quinolinone aripiprazole displayed a relative E max that was reduced 56% by the I197V SNP compared to the drug's relative efficacy at the wild-type receptor (7 vs 16, Po0.05).
The T25N SNP was associated with a significant decrease compared to wild type in relative E max for tryptamine only (56 vs 72%, Po0.05) (see Table 4 ). The A447V variant displayed a 56% increase in mCPP relative E max compared to the wild type (18 vs 28%, Po0.05) (see Figure 5 and Table 4 ). . Raw calcium flux data were normalized, with 0% being the baseline calcium flux and 100% being the maximum agonist-stimulated calcium flux, and then fit to a sigmoidal model (slope ¼ 1). For each agonist at each receptor, data from at least three independent experiments (each measured in duplicate) were analyzed simultaneously, with the log EC 50 shared among data sets. See Table 3 for the complete data matrix. While mCPP and aripiprazole both had lower E max at the H452Y 5-HT 2A receptor than at the wild type (mCPP: 3 vs 18%; aripiprazole: 3 vs 16%), the differences did not reach statistical significance (see Table 4 ). To determine whether the 5-HT 2A receptor SNPs affected receptor expression, we measured B max for each by radioligand competition binding. Except for the H452Y 5-HT 2A receptor, the expression of which was, on average, reduced 10-fold relative to the wild-type receptor, none of the SNPs altered receptor expression more than twofold compared to the wild type. Thus, the differences observed between the in vitro pharmacology of the T25N, I197V, and A447V variant 5-HT 2A receptors relative to the wild type probably do not arise due to differential expression. In addition, the fact that differences in antipsychotic pharmacology for each of the variant 5-HT 2A receptors studied herein (including the H452Y variant, which is expressed at comparatively lower levels relative to the other receptors) are not global (i.e., for a given polymorph, not all drugs are affected to the same extent) further suggests that the observed effects are not related to differences in receptor expression levels.
Discussion
The major finding of this study is that 5-HT 2A receptor SNPs can alter the in vitro pharmacology of some atypical antipsychotics as well as agonist potencies for classical 5-HT 2A agonists as well as the weak partial agonist aripiprazole. Despite numerous association studies in patient The raw data were normalized to the baseline (0%) and the maximal 5-HT response (100%) and then fit to a sigmoidal model (slope ¼ 1). Results from several experiments were analyzed simultaneously, with the maximum response shared among data sets. See Table 4 for the complete data matrix. Relative efficacy (E max ) for each drug at a given receptor was determined by fitting 5-HT concentration-response isotherms to a sigmoidal model (slope ¼ 1) to obtain estimates of the baseline and maximal 5-HT response (RFU) and then normalizing the raw RFU values using the baseline as 0% and the maximal 5-HT response as 100%. For each drug at a given receptor, the normalized concentration-response results from at least three independent experiments (measured in duplicate) were fit to a sigmoidal model (slope ¼ 1), constraining the baseline to 0 and sharing E max among data sets. *Po0.05 by F-test. Bold values significant at Po0.005.
Differential pharmacology of 5-HT 2A SNPs
populations, limited progress in genotype-based predictions of therapeutic response to antipsychotic drug therapy is evident. Because antipsychotic drugs bind to at least 50 distinct molecular targets 15 -each of which has numerous variants -it is essentially impossible to predict a priori which particular drug-variant response is likely to be involved in a particular drug response. As we have clearly demonstrated in the current study, even polymorphisms predicted to induce relatively trivial changes in the overall three-dimensional structure of a given molecular target (T25N for instance) can have unpredictably substantial effects on a given drug's in vitro pharmacology. We suggest, therefore, that an approach whereby the pharmacology of individual variants is thoroughly interrogated will yield invaluable information regarding the design and interpretation of clinical studies.
Several prior association studies have examined the relationship between 5-HT 2A receptor SNPs and atypical antipsychotic drug response. 11, 34 Most of the patients in the aforementioned studies met the criteria for treatment refractoriness or intolerance to typical antipsychotic therapy. 35 The H452Y variant is the most widely studied 5-HT 2A receptor SNP. Two studies 26, 36 reported a statistically significant association between the frequency of the Try452 allele and poor response to clozapine; a third study 27 reported a higher frequency of the Try452 allele among clozapine non-responders than in responders, although the difference between groups was not statistically significant. Notably, the Malhorta et al. study examined a smaller sample size than the Arranz et al. and Masellis et al. studies. A meta-analysis 29 of the association between H452Y and clozapine response (373 responders and 360 non-responders) showed significant association between the Tyr452 allele and poor response to clozapine (w 2 ¼ 6.97, P ¼ 0.008, OR ¼ 1.60); Tyr452 homozygosity was also related to poor clozapine response (w 2 ¼ 4.25, P ¼ 0.04, OR ¼ 5.55). We found no difference in clozapine's affinity or apparent antagonist potency at the H452Y polymorphism; thus, differences in clozapine's efficacy in populations carrying the H452Y mutation are not likely due to alterations in clozapine affinity or apparent antagonist potency.
Only one association study 37 addressed -and failed to detect -a link between the T25N SNP and clozapine response. We found no effect of the T25N polymorphism on clozapine affinity or efficacy. Instead, our findings imply that if any SNP is likely to affect clozapine response in patients, it would be the I197V variant, as clozapine's affinity and apparent antagonist potency were modestly altered.
While most association studies focused on clozapine response, one study 30 examined the association between 5-HT 2A SNPs and clinical response to olanzapine. The study reported no correlation between T25N and H452Y SNPs and 6-week olanzapine response. Based on results from the current study, we would predict that olanzapine responses would not be altered by any of the tested SNPs, as none of them dramatically altered olanzapine affinity or potency.
For the other atypical antipsychotic drugs tested, our data would imply that individuals carrying the I197V variant might show altered responses to quetiapine and, perhaps, ziprasidone. For aripiprazole, the most dramatic change was seen for aripiprazole's agonist potency at the T25N polymorphism. Here, aripiprazole showed a dramatic 30-fold decrease in agonist potency. The clinical relevance for this loss of potency at the 5-HT 2A receptor is currently unclear, although it could be related to side effects (e.g., agitation, insomnia) that are seen early in the course of aripiprazole therapy. 38 Our data would predict that individuals with the T25N polymorphism would be less susceptible to agitation and insomnia -assuming these side effects are related in a causal way to 5-HT 2A agonism.
Several biochemical studies are particularly relevant to the current project because they examined whether selected SNPs affected the in vitro pharmacology of certain agonists and antagonists at the 5-HT 2A receptor. For instance, Hazelwood and Sanders-Bush 39 recently reported that the Tyr452 5-HT 2A receptor exhibited impaired signal transduction in NIH3T3 cells compared to the His452 variant. The preceding conclusion was based upon measurements of (1) phospholipase C and D activation by agonist, (2) agonist high-affinity binding capacity, and (3) (Table 4 ) and inositol phosphate accumulation (data not shown), suggesting that the SNP might exert cell type-and/or drug-specific effects. However, we did notice a significant reduction in B max of the H452Y receptor compared with wild-type and the other 5-HT 2A receptor variants in transiently transfected cells, a finding in line with those of Hazelwood and Sanders-Bush. Another study 28 assessed signal transduction of four polymorphic 5-HT 2A receptors (T25N, I197V, A447V, or H452Y) in insect cells (Sf9). Although the latter study uncovered no differences among the SNPs in loxapine antagonist potency, the authors did measure a twofold reduction in clozapine's apparent antagonist potency at the I197V polymorphism. We, however, uncovered a 10-fold increase in clozapine's apparent antagonist potency at the I197V 5-HT 2A receptor compared with the wild-type receptor. One possible explanation for this discrepancy is that Harvey et al. expressed human 5-HT 2A receptors in Sf9 insect cells whereas we employed a human cell line (human embryonic kidney 293 (HEK-293)) expressing 5-HT 2A receptors. Indeed, the activity/function of 5-HT 2A receptors is known to be affected by the cellular context (e.g., cellular G-protein complement, receptor interacting proteins) in which the receptor is expressed. 40, 41 Two studies 42, 43 examined intracellular, 5-HT-induced calcium release in platelets. In one study of 16 seasonal affective disorder patients, Ozaki et al. 42 reported a significantly smaller rise in 5-HT-stimulated intracellular calcium flux in 452 heterozygote (His452/Tyr452) cells compared to His452 homozygote cells. Such an effect is consistent with a reduced B max (our findings) and/or an impairment in signaling (Hazelwood and Sanders-Bush's findings). In another study of 27 psychiatrically interviewed subjects (including both impulsive patients and controls), Reist et al. 43 reported that platelets from individuals with increased impulsivity measures exhibited diminished 5-HT receptor function compared to platelets isolated from less impulsive subjects. Furthermore, in the Reist et al. 43 study, platelets from a Tyr452/Tyr452 homozygote displayed reduced 5-HTstimulated intracellular calcium flux, in agreement with the findings of Ozaki et al. 42 In summary, our findings indicate that 5-HT 2A receptor SNPs can alter the in vitro pharmacology of some atypical antipsychotics. While we did not observe any large (i.e., greater than threefold) changes in atypical antipsychotic affinity (pK i ) due to the SNPs, we did observe a 10-fold increase in clozapine's apparent antagonist potency due to the I197V SNP. We also measured a threefold increase in risperidone's apparent antagonist potency due to the H452Y SNP. These increases in apparent antagonist potency demonstrate that the I197V and H452Y SNPs can increase the antagonist properties of some atypical antipsychotics absent any effect on binding affinity. While most association studies have focused on the H452Y polymorphism, our data highlight the need for studies of atypical antipsychotic efficacy in patients with rarer 5-HT 2A polymorphisms. In this regard, we demonstrate that the T25N, I197V, and H452Y 5-HT 2A receptor polymorphisms exhibit pronounced differences from the wild-type receptor. For instance, inasmuch as the therapeutic actions of clozapine are due to 5-HT 2A antagonism, the 10-fold increased apparent antagonist potency of clozapine at the I197V polymorph suggests that patients with a Val197 allele might respond better to the drug than Ile197 homozygotes.
Lastly, an in vitro pharmacological approach that examines the structure and function of receptor polymorphisms could lend important information to understanding predisposition to psychotic illness. More specifically, because use of hallucinogens, which exert their effects via activation of 5-HT 2A receptors, 16, 17 can increase the risk of developing psychotic illnesses, 44 we assessed whether SNPs altered the affinity and relative efficacy of several 5-HT 2A receptor agonists. Our data demonstrated a 10-fold decrease in DOI potency and the 36% decrease in DOI relative efficacy due to the H452Y and I197V SNPs, respectively, along with the 30% decrease in 5-methoxy-DMT relative efficacy due to the I97V SNP. These results might suggest that patients bearing the Tyr452 and Val197 alleles are differentially susceptible to psychotic illness associated with hallucinogen use.
Materials and methods

Mutagenesis
The human 5-HT 2A cDNA cloned into the NotI site pIRESneo (Clonetech) was obtained through the resources of the National Institute of Mental Health Psychoactive Drug Screening Program (http:\kidb. pdsp.cwru.edu). 45 The following mutagenesis primers were obtained from Invitrogen: SNPs were introduced into the cloned human 5-HT 2A receptor template using the QuikChange site directed, PCR-based mutagenesis kit exactly as described by the manufacturer (Stratagene, La Jolla, CA, USA). Mutagenized clones were isolated and subjected to automated DNA sequencing to verify the entire coding sequence for the presence of the desired mutation and the absence of any PCR-induced sequence errors.
Cell culture and transfection HEK-293 cells were maintained at 371C, 5% CO 2 in 75 cm 2 flasks (Costar) with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, penicillin (100 U/ml), and streptomycin (100 mg/ml) (all from Invitrogen). Transient transfection was performed in 10 cm 2 dishes using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's recommendations. One day after transfection, the cells were processed for either radioligand binding assays or intracellular calcium flux assays. For radioligand binding assays, the medium was changed to DMEM containing 5% dialyzed FBS (Invitrogen), 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin. The next day, the cells were serum starved overnight in DMEM supplemented with 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin. Finally, the cells were harvested by scraping, pelleted by centrifugation, and resuspended in 1 ml ice-cold lysis buffer (50 mM Tris-HCl, pH 6.9), after which the membrane fraction was harvested by centrifugation. Membrane fractions were frozen at À801C, if not used immediately for radioligand binding assays. For intracellular calcium flux assays, transfected cells were trypsinized, pelleted by centrifugation, and resuspended in DMEM containing 5% dialyzed FBS (Invitrogen), 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin to yield an 800 cells/ml suspension. Then, 100 ml of cell suspension was added to each well of a poly-L-lysine-coated, glass bottom 96-well plate. The next day, the medium was removed and replaced with serum-free DMEM supplemented with 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin. After an overnight serum depriva-tion, intracellular calcium flux assays were performed using a Molecular Devices Calcium Plus Assay kit and a FLEX Station II fluorescence plate reader (Molecular Devices).
Radioligand competition binding assays
Radioligand binding assays were set up in 24 wells of a 96-well plate (1 ml/well capacity) as follows: 25 ml of 10 mM [ 3 H]ketanserin (Perkin-Elmer), 25 ml of membrane pellet that had been resuspended in 700 ml ice-cold binding buffer (50 mM Tris-HCl, 5 mM MgCl 2 , 0.5 mM EDTA, pH 7.4), 25 ml vehicle (binding buffer) or 10 Â test compound (dissolved in binding buffer) at various concentrations spanning seven orders of magnitude (two wells/concentration), and 200 ml binding buffer, such that the final [ 3 H]ketanserin concentration and test compound concentrations were 1 Â . Reactions were equilibrated in the dark for 1 h at room temperature (B221C), and then receptor-ligand complexes were harvested by vacuum filtration onto Whatman GF/C filters and washed three times with ice-cold 50 mM Tris-HCl, pH 6.9 using a Brandel 24-well harvester. The filters were dried overnight, and each was added to a vial containing 4 ml EcoScint liquid scintillation cocktail (National Diagnostics). The total [
3 H]ketanserin binding present on each filter was quantified by liquid scintillation counting using a Wallac LSC. The log K D (for ketanserin) or log K i (for all other compounds) and B max values were determined using Prism 4.0 (GraphPad) by fitting the average total [ 3 H]ketanserin binding disintegrations per minute (in DPM) from several independent experiments, plotted as a function of the log(compound), to a homologous (for ketanserin) or heterologous (for all other compounds) competition model that takes into account ligand depletion (GraphPad) and shares the log K D or log K i among all data sets; B max was then fit for each experiment.
Agonist concentration-response studies For HEK-293 cells transiently expressing wild-type or polymorphic 5-HT 2A receptors, measurements of intracellular calcium flux were performed with a Molecular Devices 96-well FLEX Station II as previously detailed 46, 47 with a few modifications. Briefly, cells were washed once with 100 ml serum-free, indicator-free DMEM. Lyophilized calcium-sensitive dye (Calcium Plus Assay kit, Molecular Devices) was reconstituted with 15 ml 1 Â HBSS, 1 mM HEPES, and 2.5 mM probenecid, pH 7.4, and 30 ml of reconstituted dye was added to each well. The cells were incubated with dye for 1 h prior to agonist challenge. Agonists were diluted to 2 Â concentrations spanning at least five orders of magnitude. During the assay, after measuring the baseline 525-nM fluorescence for 20 s, 30 ml of buffer or 2 Â agonist dilutions was added in duplicate to the cells and the fluorescence measured for 50 s. The response was determined by subtracting the baseline fluorescence from the maximum agonist-stimulated fluorescence. The response data for a given agonist and 5-HT were fit simultaneously to a sigmoidal concentration-response model (slope ¼ 1) (GraphPad Prism 4.0) with the baseline a shared parameter. The raw fluorescence data were then normalized with the baseline estimate set to 0% and the estimated E max for 5-HT set to 100%. The normalized data for a given agonist from at least three independent experiments were analyzed simultaneously with the baseline constrained to 0% and the E max shared among data sets.
Apparent antagonist potency estimation
Apparent antagonist potency at inhibiting 5-HT-stimulated calcium flux via 5-HT 2A receptor blockade was determined as previously described for muscarinic receptors. 48 Briefly, agonist concentration-response assays were performed as described above. However, after the first 30 min of incubation with dye, 30 ml of buffer or 2 Â antagonist was added to the cells. 5-HT was prepared at 6 Â dilutions and added to an equal volume of buffer or 2 Â antagonist to yield 3 Â agonist71 Â antagonist dilutions. During the assay, after measurement of the baseline fluorescence for 20 s, 30 ml of 3 Â agonist71 Â antagonist was added to the cells and the fluorescence measured for 50 s. Concentration-response curves for 5-HT in the absence or presence of increasing concentrations of antagonist were generated by simultaneously fitting the data to a sigmoidal model (slope ¼ 1), sharing the baseline among the 5-HT7antagonist curves. Then, an equi-efficacious concentration of 5-HT (i.e., the pEC 25 ) was identified for each condition (i.e., absence or presence of antagonist dilutions) and fit to the modified Lew-Angus equation 49 (built into GraphPad Prism 4.0) 48 to determine the apparent antagonist potency. Results from at least three independent experiments, each performed in duplicate, were analyzed simultaneously with the apparent antagonist potency shared among data sets.
